Literature DB >> 27668050

Farydak (Panobinostat): First HDAC Inhibitor Approved for Patients with Relapsed Multiple Myeloma.

Lisa A Raedler.   

Abstract

Entities:  

Year:  2016        PMID： 27668050      PMCID： PMC5013857     

Source DB:  PubMed          Journal:  Am Health Drug Benefits        ISSN： 1942-2962


× No keyword cloud information.
  3 in total

1.  A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.

Authors:  Maria T Petrucci; Pilar Giraldo; Paolo Corradini; Adriana Teixeira; Meletios A Dimopoulos; Igor W Blau; Johannes Drach; Ralf Angermund; Nathalie Allietta; Esther Broer; Vivien Mitchell; Joan Bladé
Journal:  Br J Haematol       Date:  2013-01-07       Impact factor: 6.998

2.  Economic burden of metastatic bone disease in the U.S.

Authors:  Kathy L Schulman; Joseph Kohles
Journal:  Cancer       Date:  2007-06-01       Impact factor: 6.860

Review 3.  New strategies in the treatment of multiple myeloma.

Authors:  Nikhil C Munshi; Kenneth C Anderson
Journal:  Clin Cancer Res       Date:  2013-03-20       Impact factor: 12.531
  3 in total
  21 in total

Review 1.  Epigenetic Mechanisms in DNA Double Strand Break Repair: A Clinical Review.

Authors:  Alejandra Fernandez; Connor O'Leary; Kenneth J O'Byrne; Joshua Burgess; Derek J Richard; Amila Suraweera
Journal:  Front Mol Biosci       Date:  2021-07-07

2.  Design, synthesis, and biological evaluation of histone deacetylase inhibitor with novel salicylamide zinc binding group.

Authors:  Ji Hyun Kim; Khan Hashim Ali; Yong Jin Oh; Young Ho Seo
Journal:  Medicine (Baltimore)       Date:  2022-04-29       Impact factor: 1.817

3.  PHF20 positively regulates osteoblast differentiation via increasing the expression and activation of Runx2 with enrichment of H3K4me3.

Authors:  Jin-Woo Yang; Byung-Chul Jeong; Jongsun Park; Jeong-Tae Koh
Journal:  Sci Rep       Date:  2017-08-14       Impact factor: 4.379

Review 4.  The Process and Strategy for Developing Selective Histone Deacetylase 3 Inhibitors.

Authors:  Fangyuan Cao; Martijn R H Zwinderman; Frank J Dekker
Journal:  Molecules       Date:  2018-03-02       Impact factor: 4.411

Review 5.  Epigenetics in Sepsis: Understanding Its Role in Endothelial Dysfunction, Immunosuppression, and Potential Therapeutics.

Authors:  Deborah Cross; Ruth Drury; Jennifer Hill; Andrew J Pollard
Journal:  Front Immunol       Date:  2019-06-18       Impact factor: 7.561

Review 6.  Control of viral infections by epigenetic-targeted therapy.

Authors:  Zeina Nehme; Sébastien Pasquereau; Georges Herbein
Journal:  Clin Epigenetics       Date:  2019-03-27       Impact factor: 6.551

7.  Design, synthesis and biological evaluation of a series of CNS penetrant HDAC inhibitors structurally derived from amyloid-β probes.

Authors:  Myeong A Choi; Sun You Park; Hye Yun Chae; Yoojin Song; Chiranjeev Sharma; Young Ho Seo
Journal:  Sci Rep       Date:  2019-09-12       Impact factor: 4.379

8.  Targeting histone deacetylase 3 (HDAC3) in the bone marrow microenvironment inhibits multiple myeloma proliferation by modulating exosomes and IL-6 trans-signaling.

Authors:  Kenneth C Anderson; Peter O'Gorman; Giada Bianchi; Matthew Ho; Tianzeng Chen; Jiye Liu; Paul Dowling; Teru Hideshima; Li Zhang; Eugenio Morelli; Gulden Camci-Unal; Xinchen Wu; Yu-Tzu Tai; Kenneth Wen; Mehmet Samur; Robert L Schlossman; Ralph Mazitschek; Emma L Kavanagh; Sinéad Lindsay; Takeshi Harada; Amanda McCann
Journal:  Leukemia       Date:  2019-05-29       Impact factor: 11.528

9.  Identification of plicamycin, TG02, panobinostat, lestaurtinib, and GDC-0084 as promising compounds for the treatment of central nervous system infections caused by the free-living amebae Naegleria, Acanthamoeba and Balamuthia.

Authors:  Monica M Kangussu-Marcolino; Gretchen M Ehrenkaufer; Emily Chen; Anjan Debnath; Upinder Singh
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2019-10-22       Impact factor: 4.284

10.  Cancer-derived exosomes loaded with ultrathin palladium nanosheets for targeted bioorthogonal catalysis.

Authors:  María Sancho-Albero; Belén Rubio-Ruiz; Ana M Pérez-López; Víctor Sebastián; Pilar Martín-Duque; Manuel Arruebo; Jesús Santamaría; Asier Unciti-Broceta
Journal:  Nat Catal       Date:  2019-09-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.